Detail akcie Cumberland Ph online

Business Summary: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Cumberland Pharmaceuticals, Inc. revenues increased 18% to $44.5M. Net loss decreased 56% to $2.8M. Revenues reflect Sancuso segment increase of 32% to $11.9M, Other segment increase from $1.3M to $4.1M. Lower net loss reflects Advertising costs decrease of 9% to $2.7M (expense), Interest Income increase of 43% to $477K (income).